Robotic thymectomy in thymic tumors: a multicenter, nation-wide study
Giovanni Maria Comacchio,Marco Schiavon,Carmelina Cristina Zirafa,Angela De Palma,Roberto Scaramuzzi,Elisa Meacci,Stefano Bongiolatti,Nicola Monaci,Paraskevas Lyberis,Pierluigi Novellis,Jury Brandolini,Sara Parini,Sara Ricciardi,Antonio D'Andrilli,Edoardo Bottoni,Filippo Tommaso Gallina,Maria Carlotta Marino,Giulia Lorenzoni,Andrea Francavilla,Erino Angelo Rendina,Giuseppe Cardillo,Ottavio Rena,Piergiorgio Solli,Marco Alloisio,Luca Luzzi,Francesco Facciolo,Luca Voltolini,Stefano Margaritora,Carlo Curcio,Giuseppe Marulli,Enrico Ruffini,Giulia Veronesi,Franca Melfi,Federico Rea
DOI: https://doi.org/10.1093/ejcts/ezae178
IF: 4.534
2024-04-25
European Journal of Cardio-Thoracic Surgery
Abstract:Abstract Objectives Robotic thymectomy has been suggested and considered technically feasible for thymic tumors. However, because of small-sample series and the lack of data on long-term results, controversies still exist on surgical and oncological results with this approach. We performed a large national multicenter study sought to evaluate the early and long-term outcomes after robot-assisted thoracoscopic thymectomy in thymic epithelial tumors. Methods All patients with thymic epithelial tumors operated through a robotic thoracoscopic approach between 2002 and 2022 from 15 Italian centers were enrolled. Demographic characteristics, clinical, intraoperative, postoperative, pathological and follow-up data were retrospectively collected and reviewed. Results There were 669 patients (307 men and 362 women), 312 (46.6%) of whom had associated myasthenia gravis. Complete thymectomy was performed in 657 (98%) cases and in 57 (8.5%) patients resection of other structures was necessary, with a R0 resection in all but 9 patients (98.6%). Twenty-three patients (3.4%) needed open conversion, but no perioperative mortality occurred. Fifty-one patients (7.7%) had postoperative complications. Median diameter of tumor resected was 4cm (interquartile range 3-5.5cm), and Masaoka stage was stage I in 39.8% of patients, stage II in 56.1%, stage III in 3.5% and stage IV in 0.6%. Thymoma was observed in 90.2% of patients while thymic carcinoma occurred in 2.8% of cases. At the end of the follow-up, only 2 patients died for tumor-related causes. Five and ten-year recurrence rates were 7.4% and 8.3%, respectively. Conclusions Through the largest collection of robotic thymectomy for thymic epithelial tumors we demonstrated that robot-enhanced thoracoscopic thymectomy is a technically sound and safe procedure with a low complication rate and optimal oncological outcomes.
surgery,cardiac & cardiovascular systems,respiratory system